GeoVax Labs, Inc. (GOVX) · Nov 19, 2026 · Exec change
CFO departure — CFO resigned; fractional replacement hired at $10,000 per month
GeoVax’s latest executive-change filing replaces its CFO with a fractional consultant, adding continuity but deepening questions around leadership stability.
GeoVax is a cash-constrained clinical-stage biotech trying to advance its GEO-MVA mpox/smallpox vaccine toward a planned late-2026 Phase 3 trial, while also developing Gedeptin in oncology. Its latest quarterly filing said available resources were expected to fund operations only into December 2026 and raised substantial doubt about its ability to continue as a going concern.
The CFO transition adds to an already unsettled leadership picture. Mark Reynolds resigned on November 13, only days after David Dodd was terminated as CEO and Tyler O’Brien was installed as interim CEO and chairman. 〔0〕 The filing does not identify a business-performance reason for Reynolds’s exit, so it is not evidence of a newly discovered accounting problem; the issue is continuity while the company is trying to secure capital and execute near-term clinical plans.
The replacement preserves finance coverage but is not a full stabilization signal. Anna Skowron becomes CFO and principal financial and accounting officer through BPC Consulting on a fractional, non-employee basis. 〔1〕 That structure may limit fixed overhead, but it also suggests GeoVax is operating with a lean, temporary management model rather than rebuilding a permanent executive team.
| Compensation / term | Filing figure | Comparison |
|---|---|---|
| CFO consulting fee (CFO Consulting Agreement) | $10,000/month | 90-day notice |
| Interim CEO consulting fee (O’Brien Consulting Agreement) | $15,000/month | 90-day notice |
The terms are manageable, but the filing does not extend the runway or advance the pipeline. BPC will receive $10,000 per month, while O’Brien’s previously disclosed interim CEO arrangement pays $15,000 per month. The costs are small relative to the company’s financing needs, but the filing brings no new funding, clinical milestone, or regulatory progress; it mainly formalizes a temporary leadership structure as GeoVax approaches a financing-dependent Phase 3 decision.
Bottom line: This is a modestly negative governance and execution signal, not a pipeline event. The fractional CFO keeps reporting functions covered, but the broader story remains a cash-constrained biotech operating through a continuing leadership reset.
Permanent CEO appointment
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!